• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Disputes over the production and dissemination of misinformation in the time of COVID-19.在 COVID-19 时代,错误信息的产生和传播引发争议。
Respir Med. 2021 Jun;182:106380. doi: 10.1016/j.rmed.2021.106380. Epub 2021 Mar 29.
2
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.PROTECT 试验:羟氯喹对比观察支持用于预防或 COVID-19 早期治疗的一项集群随机对照研究:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4.
3
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效:III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
6
Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19.对《COVID-19 高风险门诊患者羟氯喹和阿奇霉素联合治疗的专论》的担忧。
Am J Epidemiol. 2021 Apr 6;190(4):491-495. doi: 10.1093/aje/kwaa189.
7
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.羟氯喹和阿奇霉素联合对抗 SARS-CoV-2 的协同抗病毒作用:病毒-宿主相互作用的分子动力学研究揭示了什么。
Int J Antimicrob Agents. 2020 Aug;56(2):106020. doi: 10.1016/j.ijantimicag.2020.106020. Epub 2020 May 13.
8
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.羟氯喹和阿奇霉素联合治疗 COVID-19 患者:法国马赛 1061 例回顾性分析。
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
9
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.羟氯喹和阿奇霉素联合治疗 SARS-CoV-2 的协同抗病毒作用:病毒-宿主相互作用的分子动力学研究揭示了什么。
Int J Antimicrob Agents. 2020 Aug;56(2):106020. doi: 10.1016/j.ijantimicag.2020.106020. Epub 2020 May 13.
10
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.巴基斯坦评估羟氯喹、奥司他韦和阿奇霉素治疗新冠病毒感染的随机和观察性试验(PROTECT):针对无糖尿病等合并症的新发 COVID-19 感染患者的治疗:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Aug 8;21(1):702. doi: 10.1186/s13063-020-04616-4.

引用本文的文献

1
Analysis of Differences in User Groups and Post Sentiment of COVID-19 Vaccine Hesitators in Chinese Social-Media Platforms.中国社交媒体平台上新冠疫苗犹豫者用户群体及帖子情绪差异分析
Healthcare (Basel). 2023 Apr 23;11(9):1207. doi: 10.3390/healthcare11091207.
2
Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.COVID-19 早期的家庭药物治疗以预防住院和降低死亡率:是时候提出一个合适的建议了。
Basic Clin Pharmacol Toxicol. 2022 Feb;130(2):225-239. doi: 10.1111/bcpt.13690. Epub 2021 Dec 2.
3
Prevalence and predictors of self-medication drugs to prevent or treat COVID-19: Experience from a Middle Eastern country.预防或治疗 COVID-19 而自我用药的流行情况和预测因素:来自中东国家的经验。
Int J Clin Pract. 2021 Nov;75(11):e14860. doi: 10.1111/ijcp.14860. Epub 2021 Sep 19.
4
Controversy surrounding the Sputnik V vaccine.关于卫星 V 疫苗的争议。
Respir Med. 2021 Oct;187:106569. doi: 10.1016/j.rmed.2021.106569. Epub 2021 Aug 10.

本文引用的文献

1
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
2
Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.低维生素 D 状态与 COVID-19 住院患者不良预后的相关性:意大利回顾性研究。
J Am Nutr Assoc. 2022 Mar-Apr;41(3):250-265. doi: 10.1080/07315724.2021.1877580. Epub 2021 Feb 18.
3
Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations.为感染新冠病毒的有症状患者提供预防性家庭治疗,并进行远程会诊。
Multidiscip Respir Med. 2021 Jan 18;16(1):748. doi: 10.4081/mrm.2021.748. eCollection 2021 Jan 15.
4
Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.氯喹和羟氯喹治疗 COVID-19:一个永无止境的故事。
Appl Microbiol Biotechnol. 2021 Feb;105(4):1333-1343. doi: 10.1007/s00253-021-11094-4. Epub 2021 Jan 30.
5
Vitamin D and COVID-19: why the controversy?维生素D与2019冠状病毒病:为何存在争议?
Lancet Diabetes Endocrinol. 2021 Feb;9(2):53. doi: 10.1016/S2213-8587(21)00003-6. Epub 2021 Jan 11.
6
The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial.维生素 D 补充对老年澳大利亚成年人急性呼吸道感染的影响:来自 D-Health 试验的数据分析。
Lancet Diabetes Endocrinol. 2021 Feb;9(2):69-81. doi: 10.1016/S2213-8587(20)30380-6. Epub 2021 Jan 11.
7
Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic.2019年冠状病毒病大流行期间与临床试验研究相关的障碍和考量因素
Front Med (Lausanne). 2020 Dec 23;7:598038. doi: 10.3389/fmed.2020.598038. eCollection 2020.
8
Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.早期使用皮质类固醇与 COVID-19 重症患者的死亡率降低有关:一项队列研究。
Crit Care. 2021 Jan 4;25(1):2. doi: 10.1186/s13054-020-03422-3.
9
Generating evidence for therapeutic effects: the need for well-conducted randomized trials.生成治疗效果的证据:开展良好的随机试验的必要性。
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI146391.
10
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.

在 COVID-19 时代,错误信息的产生和传播引发争议。

Disputes over the production and dissemination of misinformation in the time of COVID-19.

机构信息

Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Respir Med. 2021 Jun;182:106380. doi: 10.1016/j.rmed.2021.106380. Epub 2021 Mar 29.

DOI:10.1016/j.rmed.2021.106380
PMID:33930690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8006495/
Abstract

Ultimate coronavirus disease 2019 (COVID-19) mitigation and crisis resolution is dependent on trustworthy data and actionable information. At present time, there is still no cure for COVID-19, although some treatments are being used in severe illness. Regrettably, as the SARS-CoV-2 virus spreads, the lack of cure has been accompanied by an increasing amount of medical misinformation. In particular, there is a lot of misinformation about how to treat patients who have tested positive for SARS-CoV-2 and who are asymptomatic or have mild symptoms and for whom management at home is deemed appropriate. In this editorial, we highlight the risks deriving from this misinformation, which often arises from the publication of studies that are not conceptually and methodologically accurate.

摘要

最终的 2019 年冠状病毒病(COVID-19)缓解和危机解决方案取决于可靠的数据和可操作的信息。目前,虽然在重症疾病中使用了一些治疗方法,但 COVID-19 仍无法治愈。遗憾的是,随着 SARS-CoV-2 病毒的传播,缺乏治愈方法的同时,也出现了越来越多的医疗错误信息。特别是,关于如何治疗 SARS-CoV-2 检测呈阳性且无症状或症状轻微的患者,以及对于哪些患者适合在家管理,存在大量错误信息。在本社论中,我们强调了这些错误信息带来的风险,这些错误信息通常源于那些在概念和方法上不准确的研究的发表。